Vascular Biogenics (VBLT)
NASDAQ:VBLT
US Market

Vascular Biogenics Stock Price & Analysis

709 Followers

VBLT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.11 - $2.35
Previous Close$0.16
Volume1.47M
Average Volume (3M)1.44M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$27.38M
Total Debt (Recent Filing)$731.00K
Price to Earnings (P/E)-0.3
Beta-0.13
Next EarningsMar 23, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
EPS (TTM)-0.51
Shares Outstanding69,750,117
R-Squared0.03
Standard Deviation0.20
10 Day Avg. Volume1,907,778
30 Day Avg. Volume1,443,387
Price to Book (P/B)0.44
Price to Sales (P/S)13.06
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target UpsideN/A
Rating ConsensusHold
Alpha-0.03
Number of Analyst Covering1


Financials


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

VBLT FAQ

What was Vascular Biogenics’s price range in the past 12 months?
Vascular Biogenics lowest stock price was $0.11 and its highest was $2.35 in the past 12 months.
    What is Vascular Biogenics’s market cap?
    Currently, no data Available
    When is Vascular Biogenics’s upcoming earnings report date?
    Vascular Biogenics’s upcoming earnings report date is Mar 23, 2023 which is in 111 days.
      How were Vascular Biogenics’s earnings last quarter?
      Vascular Biogenics released its earnings results on Nov 14, 2022. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.01.
        Is Vascular Biogenics overvalued?
        According to Wall Street analysts Vascular Biogenics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Vascular Biogenics pay dividends?
          Vascular Biogenics does not currently pay dividends.
          What is Vascular Biogenics’s EPS estimate?
          Vascular Biogenics’s EPS estimate is -$0.14.
            How many shares outstanding does Vascular Biogenics have?
            Vascular Biogenics has 69,337,310 shares outstanding.
              What happened to Vascular Biogenics’s price movement after its last earnings report?
              Vascular Biogenics reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went up 8.333%.
                Which hedge fund is a major shareholder of Vascular Biogenics?
                Among the largest hedge funds holding Vascular Biogenics’s share is ARK Investment Management LLC. It holds Vascular Biogenics’s shares valued at N/A.

                  ---

                  Vascular Biogenics Stock Smart Score

                  N/A
                  Not Ranked
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -93.14%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -100.18%
                  Trailing 12-Months
                  Asset Growth
                  -41.89%
                  Trailing 12-Months
                  This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Vascular Biogenics

                  Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Neurosense Therapeutics Ltd.
                  Entera Bio
                  ViewBix
                  BiomX

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis